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Abstract
Background: Growth hormone (GH) treatment may unmask 
central hypothyroidism (CeH). This was first observed in chil-
dren with GH deficiency (GHD), later also in adults with GHD 
due to acquired “organic” pituitary disease. We hypothesized 
that newly diagnosed CeH in children after starting GH treat-
ment for nonacquired, apparent isolated GHD points to con-
genital “organic” pituitary disease. Methods: Nationwide, 
retrospective cohort study including all children with nonac-
quired GHD between 2001 and 2011 in The Netherlands. The 
prevalence of CeH, hypothalamic-pituitary (HP) abnormali-
ties, and neonatal congenital hypothyroidism screening re-
sults were evaluated. Results: Twenty-three (6.3%) of 367 
children with apparent isolated GHD were prescribed LT4 for 
presumed CeH within 2 years after starting GH treatment. 
Similarly to children already diagnosed with multiple pitu-
itary hormone deficiency, 75% of these 23 had structural HP 
abnormalities. In children not prescribed LT4, low pre- or 
post-GH treatment FT4 concentrations were also associated 
with structural HP abnormalities. Neonatal screening results 
of only 4 of the 23 children could be retrieved. Conclusion: 
In children with nonacquired, apparent isolated GHD, a diag-
nosis of CeH after, or a low FT4 concentration around the 
start of GH treatment, is associated with congenital struc-
tural HP abnormalities, i.e., “organic” pituitary disease. Neo-
natal values could not be judged reliably.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Since its introduction in the mid-1980s, treatment 
with human recombinant growth hormone (GH) has be-
come common practice in the fields of pediatric and adult 
endocrinology [1–3]. The influence of GH administra-
tion on the hypothalamic-pituitary-thyroid axis is well 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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recognized [4]. In non-GH-deficient individuals, GH ad-
ministration may result in slightly lower plasma or se-
rum-free thyroxine (FT4) concentrations in combination 
with higher triiodothyronine (T3) concentrations and al-
most unchanged thyroid-stimulating hormone (TSH) 
concentrations [5–7]. These changes in thyroid hormone 
levels are usually temporary and are thought to be caused 
by increased T4 to T3 conversion and inhibition of TSH 
secretion [5]. However, often FT4, T3, and TSH do not 
show any changes [8, 9].
In contrast to non-GH-deficient individuals, in pa-
tients with GH deficiency (GHD) changes are often more 
pronounced and in the last few decades, it has become 
clear that GH treatment in patients with GHD may un-
mask central hypothyroidism (CeH). CeH is defined as 
an FT4 concentration below the age-specific reference in-
terval, in combination with a low, normal or slightly ele-
vated TSH concentration [10]. Unmasking refers to a de-
crease in FT4 from within the reference range, to below 
the reference range. This was first observed in children 
with an initial diagnosis of isolated GHD, who were sub-
sequently reclassified as having multiple (or combined) 
pituitary hormone deficiency (MPHD) [11]. Later on, it 
was also reported in adults, especially in those with ac-
quired GHD due to “organic” pituitary disease, i.e., trau-
ma, tumor or after pituitary surgery [12–14].
In the past 15 years, we have also encountered several 
children with CeH shortly after starting GH treatment for 
apparent isolated GHD. Additional testing revealed cen-
tral adrenal insufficiency in a number of these patients. 
All patients had structural hypothalamic-pituitary (HP) 
abnormalities mainly consisting of an ectopic posterior 
pituitary and/or pituitary hypoplasia. In a recent MRI 
study in early childhood GHD, it was reported that all 
children with GHD as part of MPHD had complex pitu-
itary defects (i.e., ectopic posterior pituitary, with or with-
out pituitary hypoplasia, and pituitary stalk or midline 
abnormalities). In contrast, most of the children with iso-
lated GHD had a normal pituitary anatomy or only iso-
lated pituitary hypoplasia [15]. Nowadays, most pediatric 
endocrinologists perform additional pituitary function 
tests and MRI of the HP region in children diagnosed 
with GHD. Since MRI is usually not possible in young 
children without the use of general anesthesia, imaging is 
often postponed until an older age, especially when other 
pituitary deficiencies seem to be absent. Since the gonad-
al axis cannot be reliably tested beyond the first months 
of life, and the adrenal axis requires dynamic testing, the 
decision to perform MRI under general anesthesia may 
be solely guided by the presence of CeH. This raises the 
question whether low FT4 concentrations and/or a diag-
nosis of CeH at initiation of GH treatment for apparent 
GHD indicates congenital pituitary malformation.
In The Netherlands, each year 8–10 children with CeH 
are detected in the neonatal screening program for con-
genital hypothyroidism (CH; Dutch incidence: approxi-
mately 1 in 16,000) [16]. Approximately 75% of these 
children have congenital MPHD, usually including GHD 
and most of these children have pituitary malformations 
[16, 17]. These pituitary malformations are similar to 
those seen in children initially presenting with isolated 
GHD which turns out to be part of MPHD including 
CeH. These children apparently had not been detected in 
the Dutch neonatal screening program for CH. We hy-
pothesized that their neonatal thyroid hormone concen-
trations may be at the lower limit of the reference range 
but not low enough to be detected by neonatal screening.
To study the occurrence of CeH after initiation of GH 
treatment in children with congenital GHD, we conduct-
ed a nationwide, retrospective cohort study including all 
children with congenital GHD diagnosed between Janu-
ary 2001 and January 2011 in The Netherlands. To iden-
tify MPHD, we studied the presence of structural and/or 
functional HP abnormalities. In addition, we attempted 
to retrieve neonatal CH screening results.
Subjects and Methods
Patients
All children diagnosed with congenital GHD between January 
2001 and January 2011 in the Netherlands, and younger than 18 
years at the initiation of GH treatment, were eligible for the study. 
Patients were retrieved from the database of the Dutch Growth 
Research Foundation (DGRF). GHD was defined as a maximal 
plasma GH concentration ≤20 mIU/L in two GH stimulation tests 
combined with a sex- and age-specific serum IGF-1 concentration 
<0 SD, or a maximal GH ≤30 mIU/L in combination with an 
IGF-1 <–2 SD (most Dutch laboratories report GH concentrations 
in milli-international units/liter; to convert to microgram/liter, di-
vided by 3) [18]. Exclusion criteria were acquired GHD (brain tu-
mor, cranial or total body irradiation, or traumatic brain injury), 
possible (partial) GH resistance, and GH treatment for indications 
other than GHD. Children treated with levothyroxine (LT4), hy-
drocortisone, sex steroids or desmopressin prior to the start of GH 
treatment were classified as having MPHD (two or more pituitary 
deficiencies). The occurrence of CeH after the initiation of GH 
treatment was defined as a low plasma FT4 concentration in the 
presence of an inappropriately low, normal or mildly elevated 
TSH, for which LT4 treatment had been started by the child’s doc-
tor [19]. In The Netherlands, the lower limit of the adult reference 
interval of most FT4 assays is between 8 and 12 pmol/L, with an 
average of around 10 pmol/L; the average upper limit is 23 pmol/L 
(personal communications). The lower limit of most TSH assays 
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is between 0.3 and 0.5 mIU/L, with an average of around 0.4 
mIU/L; the highest reported upper limit is 5.0 mIU/L. Since inno-
cent and transitory changes in thyroid hormone levels after the 
initiation of GH treatment usually resolve within 1–2 years, we set 
the time window for the diagnosis of CeH to be made at 2 years 
after the start of GH treatment [20].
Data were extracted from the children’s hospital records and 
DGRF database files, and were cross-checked with data stored by 
the National Institute for Public Health and the Environment 
(RIVM-DVP, the organization responsible for the Dutch neonatal 
screening). MRI reports were retrospectively retrieved and classi-
fied as either “normal” or “abnormal” (reported as ectopic poste-
rior pituitary; absent or thin pituitary stalk; pituitary hypoplasia; 
empty sella). In addition, parents were asked to participate in a 
structured telephonic interview to collect information on clinical 
factors influencing neonatal thyroid function. To keep the investi-
gators blinded, with a few exceptions, interviews were performed 
before retrieval of data from hospital records, database files, and 
neonatal screening results. According to the Dutch neonatal 
screening definitions, children were classified as “premature” if 
gestational age was <36 weeks in combination with a birth weight 
<2.5 kg. “Non-thyroidal illness” was suspected when the interview 
revealed birth asphyxia (5 min Apgar score <7), use of intravenous 
antibiotics (for probable perinatal infection), weight loss of 10% or 
more (often resulting from feeding problems) or gastrointestinal 
surgery preceding the neonatal screening.
The Medical Ethics Committee of the Academic Medical Cen-
ter, the Dutch national GH advisory board and the RIVM ap-
proved the study. Written informed consent was obtained from all 
children and their parents.
Exclusion reasons:
Hospital not willing to participate n = 7
Address of patient unknown n = 4
Pediatrician refuses to approach patient
n = 4
Patients selected by the Dutch
Growth Research Foundation
n = 619
Exclusion reasons:
Patient does not respond n = 140
Patient refuses to participate n = 1
Patients approached
n = 604
Informed consent
n = 463 Exclusion reasons:
Brain tumour in medical history n = 4
Langerhans cell histiocytosis medical 
history n = 2
Brain hemorrhage in medical history 
n = 1Patients included
n = 456
Group 1: MPHD
n = 89
Group 2: Apparent isolated GHD
n = 367
MPHD
n = 9
MPHD including CeH
n = 80
MPHD
n = 6
MPHD including CeH
n = 3
Group 2b: Probable
isolated GHD
n = 344* 
Group 2a: GHD and
presumed CeH
n = 23 
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Fig. 1. Selection of patients. White boxes represent the classifica-
tion of patients at the start of growth hormone treatment; gray 
boxes represent the classification of patients 2 years after the start 
of growth hormone treatment. CeH, central hypothyroidism; 
GHD, growth hormone deficiency; MPHD, multiple pituitary hor-
mone deficiency. * Two patients with probable isolated GHD were 
prescribed thyroxine for potential primary hypothyroidism after 
the start of GH treatment (pretreatment FT4 and TSH concentra-
tions: 15.0 pmol/L and 5.6 mIU/L, and 14.1 pmol/L and 9.83 
mIU/L, respectively).
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Neonatal Screening Results
The Dutch neonatal CH screening is primarily (total) T4 based. 
TSH is measured in the 20% lowest T4 concentrations with an ad-
ditional T4-binding globulin (TBG) measurement in the 5% low-
est T4 concentrations [21]. All screening laboratories use the same 
T4, TSH, and TBG assays. Quarterly nationwide quality controls 
guarantee high reproducibility and comparability. Since screening 
results were stored in a single national RIVM database from 2002 
onward, we were not able to retrieve normal results of children 
born before that year. However, we were able to retrieve abnormal 
screening results by searching paper archives of regional screening 
centers.
Table 1. Baseline characteristics of the 456 patients at the start of GH treatment
Characteristics Group 1 (n = 89); GHD
probably within the
framework of congenital
MPHDa
Group 2 (n = 367); apparent isolated GHD
group 2a (n = 23); GHD and
presumed CeH
group 2b (n = 344b); probable 
isolated GHD
Gender (male), n (%) 63 (70.8) 15 (65.2) 230 (66.9)
Gestational age, weeks 39.0 (26.1 to 42.7) 40.0 (30.0 to 42.0) 40.0 (25.0 to 43.0)
Birth weight (SD for GA) –0.54 (–3.68 to 1.69) –0.30 (–2.70 to 2.45) –0.37 (–4.15 to 3.52)
Age, years 3.90 (0.17 to 16.11)c 4.36 (1.89 to 14.34) 5.62 (0.54 to 15.68)
Height SDS –3.00 (–6.89 to –0.03) –2.89 (–4.48 to –1.72) –2.92 (–6.69 to –0.72)
Bone age delay, years –1.3 (–6.6 to 1,0) –1.4 (–4.0 to 0.7) –1.2 (–11.4 to 0.6)
Maximum stimulated GH
concentration, mIU/Ld 8.6 (0.1 to 34.2) 13.0 (3.2 to 29.9) 16.1 (1.0-61.6)e
Thyroid function parametersf Not applicable Before the start of GH treatment Before the start of GH treatment
FT4, pmol/L 12.3 (7.6 to 19.4)g,h 15.1 (7.8 to 24.0)
TSH, mIU/L 2.10 (0.17 to 7.70) 2.34 (0.32 to 6.70)
Thyroid function parameters After the start of GH treatment 6 months (range 4–8) after the 
start of GH treatment
FT4, pmol/L 9.9 (6.6 to 12.0)h 14.0 (8.2–25.0)
TSH, mIU/L 1.98 (0.12 to 3.30) 2.60 (0.93–7.00)
Thyroid function parameters After the start of LT4 treatment 12 months (range 9–13) after the 
start of GH treatment
FT4, pmol/L 16.1 (12.0 to 20.1) 14.8 (8.1–22.8)
TSH, mIU/L 0.39 (0.01 to 3.30) 2.44 (0.52–7.75)
MRI results, n
Total available MRI results 75 21 213
Normal MRI result 19 5 150
Abnormal MRI resulti 56 16 63
Bone age delay, delay with respect to calendar age; GHD, growth hormone deficiency; MPHD, multiple (or combined) pituitary 
hormone deficiency; CeH, central hypothyroidism; SDS, standard deviation. All values are median (min. to max.), except where indicated 
otherwise. a Of the patients with MPHD, GHD was combined with central hypothyroidism only (CeH) in n = 40, with central adrenal 
insufficiency only (CeA) in n = 4, with central (or hypogonadotropic) hypogonadism only (CeHy) in n = 2, or with diabetes insipidus 
only (CeDI) in n = 2; in the other patients with MPHD, GHD was combined with both CeH and CeA in n = 36, or with both CeH and 
CeDI in n = 1; 4 patients had dysfunction of >3 pituitary axes: CeH+CeA+CeHy in n = 2, and CeH+CeA+CeDI in n = 2. b Two patients 
with probable isolated GHD were prescribed thyroxine for potential primary hypothyroidism after the start of GH treatment (pretreatment 
FT4 and TSH concentrations: 15.0 pmol/L and 5.6 mIU/L, and 14.1 pmol/L and 9.83 mIU/L, respectively). c Group 1 vs. groups 2a and 
2b, p < 0.05. d In 6 patients, maximum stimulated GH concentrations were not available, because the diagnosis GHD was based on clinical 
symptoms (n = 2), or GH was only measured during hypoglycemia (n = 2) or randomly in neonates (n = 2). e Group 2b vs. groups 1 and 
2a, p < 0.05. f The lower limits of most FT4 assays are between 8 and 12 pmol/L, with an average around 10 pmol/L. The average upper 
limit is 23 pmol/L The lower limits of most TSH assays are between 0.3 and 0.5 mIU/L, with an average around 0.4 mIU/L. The highest 
used upper limit is 5.0 mIU/L. g Group 2a vs. group 2b, p < 0.001. h Difference in FT4 concentration before and after the start of GH 
treatment within group 2a, p < 0.001. i Abnormal MRI refers to one or more of the following congenital abnormalities: ectopic posterior 
pituitary; absent or thin pituitary stalk; pituitary hypoplasia; empty sella.
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Statistical Analyses
Patients were divided into two groups: group 1 consisting of 
patients with MPHD and group 2 consisting of patients with ap-
parent isolated GHD (i.e., no treatment for other pituitary defi-
ciencies at the start of GH treatment). Group 2 was further divided 
into patients who were prescribed LT4 for presumed CeH within 
2 years after starting GH treatment (group 2a), and those who were 
not (group 2b).
Data are presented as median (min. to max.). Nonnormally dis-
tributed data in more than two categories were tested for signifi-
cance by the Kruskall-Wallis test for nonparametric measure-
ments. Two categories were compared with the Mann-Whitney U 
test. Categorical data were compared using the χ2 test. The paired 
t test was used to compare differences within groups during treat-
ment in normally distributed data and the Wilcoxon signed rank 
test in nonnormally distributed data. A value of p < 0.05 was con-
sidered statistically significant. Data were analyzed using SPSS ver-
sion 22 for Windows (IBM SPSS System Inc., Chicago, IL, USA).
Results
Patients
In the DGRF database, inclusion criteria were met by 
619 children of whom 604 could be contacted by their 
participating pediatricians (endocrinologists). Four hun-
dred and sixty-three children and parents agreed to par-
ticipate, but 7 children were excluded due to previously 
unnoticed acquired GHD, resulting in 456 children 
(Fig. 1).
Baseline Characteristics, and Thyroid Function before 
and after Starting GH Treatment
Eighty-nine of the 456 included patients were diag-
nosed with MPHD (group 1), and 367 with apparent iso-
lated GHD (group 2) before GH treatment. Twenty-three 
children in group 2 (6.3%) were prescribed LT4 treatment 
for presumed CeH diagnosed within 2 years after the ini-
tiation of GH treatment (after a median of 0.6 years, range 
0.1–1.9; group 2a). Three hundred and forty-two of the 
remaining 344 children (group 2b) were judged as having 
a normal thyroid function, while 2 children were pre-
scribed LT4 for presumed mild primary hypothyroidism. 
In 80 of the 89 children in group 1 – the MPHD group –, 
LT4 treatment was already started before GH treatment, in 
3 other children LT4 was started after initiation of GH 
treatment. Table 1 shows the baseline characteristics of the 
children in groups 1, 2a, and 2b. Compared to groups 2a 
and 2b, the children in group 1 were significantly younger 
at the start of GH treatment (3.90 vs. 4.36 and 5.62 years, 
respectively). Maximum stimulated GH concentrations 
were significantly lower in groups 1 and 2a compared to 
group 2b (8.6 vs. 13.0 and 16.1 mIU/L, respectively).
Before starting GH treatment, the median plasma FT4 
concentration of the children in group 2a was significant-
ly lower than in group 2b (12.3 vs. 15.1 pmol/L, respec-
tively; p < 0.001), while the median TSH concentrations 
were similar (online suppl. Table 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000486033). 
After starting GH treatment, the median plasma FT4 con-
centration in group 2a decreased to 9.9 pmol/L. After the 
start of LT4 treatment, median FT4 increased and TSH 
decreased from 1.98 to 0.39 mIU/L. In group 2b, the chil-
dren with presumed “normal” pituitary function, FT4 de-
creased from 15.1 pmol/L to 14.0 pmol/L, but within 1 
year FT4 spontaneously increased to 14.8 pmol/L. TSH 
did not change significantly.
Figure 2 shows scatterplots of the FT4 and TSH con-
centrations of the children in groups 2a and 2b before and 
after initiation of GH treatment. The third time point in 
these scatterplots represents the FT4 and TSH concentra-
tions on LT4 treatment in group 2a or after 1 year of GH 
treatment in group 2b. An intriguing observation is that 
a number of children in group 2b – i.e., the children 
judged as having a normal thyroid function – had a low 
or low normal FT4 concentration before and after initia-
tion of GH treatment, and also later on. Twelve of them 
were still prescribed LT4 more than 2 years after initiation 
of GH treatment (after a median of 5.1 years, range 
Fig. 2. FT4 and TSH concentrations before (a, b) and after the start 
of growth hormone treatment (c–f), in the children who were (a, 
c, e) and were not (b, d, f) treated with levothyroxine. The circles 
in a, c, and e represent the children who were diagnosed with (pre-
sumed) central hypothyroidism after the start of growth hormone 
treatment. a Before the start of growth hormone treatment. c After 
the start of growth hormone treatment, but before the start of le-
vothyroxine treatment. e After the start of levothyroxine treat-
ment. The circles in b, d, and f represent the children whose thy-
roid function was judged as “normal” before (b) and after (d) the 
start of growth hormone treatment. f Their thyroid function ap-
proximately 1 year later. The vertical and horizontal lines repre-
sent the median FT4 and TSH concentrations, respectively. The 
vertical and horizontal dashed lines represent the lower and upper 
limits of the adult FT4 and TSH reference intervals. The lower lim-
its of most FT4 assays are between 8 and 12 pmol/L, with an aver-
age around 10 pmol/L. The average upper limit is 23 pmol/L. The 
lower limits of most TSH assays are between 0.3 and 0.5 mIU/L, 
with an average around 0.4 mIU/L. The highest used upper limit 
is 5.0 mIU/L.
(For figure see next page.)
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2.9–9.8). Based on the assumption that these children 
may very well have – at that time still undiagnosed – CeH, 
and that structural abnormalities of the HP region may 
support this diagnosis, we compared the MRI results of 
the children in groups 1, 2a, and 2b, and we analyzed HP 
MRI results of the children in group 2b in relation to FT4 
at the three time points.
MRI Results
HP MRI results of 309 of the 456 included patients 
were available. Sixteen of 21 (76.2%) MRI studies of pa-
tients in group 2a showed congenital abnormalities, 
similar to the percentage of the children in group 1 (ab-
normalities in 56 of 75 [74.7%]), but clearly higher than 
the percentage in group 2b (abnormalities in 63 of 213 
[29.6%]). Sixteen of the 344 children in group 2b had 
FT4 concentrations <10 pmol/L before or at least at one 
measurement after initiation of GH treatment. In 8 of 
these 16 cases, MRI results were available and showed 
congenital abnormalities in 6 cases (75%). When this 
analysis was repeated in children with a lowest FT4 con-
centration of 10–11 pmol/L, the percentage was 57% (4 
of 7). In children with a lowest FT4 concentration of 
11–12 pmol/L, this was 25% (5 of 20). In children with 
a lowest FT4 concentration of 12–13, 13–14 and ≥14 
pmol/L, the percentages were 28.6, 26.7, and 26.8%. In 8 
of the 12 children who were prescribed LT4 more than 
2 years after the initiation of GH treatment, MRI studies 
were available, with congenital abnormalities in 5 cases 
(62.5%).
Neonatal Screening Results
Parents of 400 children were interviewed, and neona-
tal CH screening results of 225 could be retrieved. Sixty 
screening results were excluded from analysis because of 
prematurity (n = 30) or probable nonthyroidal illness 
(n = 30). Another 9 were excluded because of missing 
perinatal data. In total, screening results of 156 children 
were available for analysis. Screening results of only 4 
children in group 2a were retrieved. Their T4 concentra-
tions were clearly lower than in group 2b, but comparable 
to group 1 (median T4 SD scores –1.9 [group 2a, n = 4], 
–0.5 [group 2b, n = 126], and –2.2 [group 1, n = 26], re-
spectively; p < 0.05 for group 2b vs. groups 1 and 2a) (Ta-
ble 2). TSH concentrations were similar.
Adrenal Axis Testing Results
Assessment of the HP adrenal axis was performed in 
11 of the 23 children in group 2a after initiation of GH 
treatment. In 6 patients, a classic (250 μg) ACTH test was 
performed, in 2 a low-dose (1 μg) ACTH test, and in 1 a 
morning cortisol measurement was used to evaluate the 
HP adrenal axis. In 2 other patients, the mode of testing 
or results could not be retrieved. However, in these 2 pa-
Table 2. Neonatal screening results of the children with multiple pituitary hormone deficiency versus the children with GH deficiency 
and newly diagnosed central hypothyroidism, and those with probable isolated GH deficiency at the start of GH treatment
n T4 (SD
score)
Min. to max. n TSH,
mIU/L
Min. to max. n TBG, 
nmol/L
Min. to max. n T4/TBG
ratio
Min. to max.
Neonatal screening results, minus excluded resultsa
Group 1 26 –2.2 –4.3 to 1.4 20 1.50 0.50 to 4.50 18 195.5 113.0 to 345.0 18 13.0 5.8 to 21.3
Group 2a 4 –1.9 –3.0 to –0.4 3 1.50 1.50 to 2.00 3 160.5 107.5 to 174.0 3 19.6 19.4 to 19.6
Group 2b 126 –0.5b –2.9 to 2.3 34 1.50 0.50 to 5.50 10 166.0 105.0 to 224.0 10 19.8 12.6 to 29.6
T4 (SD
score)
TSH,
mIU/L
TBG, nmol/L T4/TBG
ratio
Result
Individual neonatal screening results group 2a
Subject
6c –3.8 4.00 71.5 18.2 Negative
7 –0.4 Negative
16c –1.8 1.00 184.0 17.9 Negative
17d –3.0 1.50 107.5 19.6 Positive
19 –1.7 1.50 174.0 19.6 Negative
20 –2.0 2.00 160.5 19.4 Negative
a Sixty neonatal screening results were excluded from the analysis because of prematurity (n = 30) or probable nonthyroidal illness(n = 30). Another 9 results were excluded because 
of missing perinatal data. b Group 2b vs. groups 1 and 2a: p < 0.05. c Excluded neonatal screening results in group 2a: subject 6, for prematurity (gestational age 30 weeks, birth weight 
810 g); subject 16, for probable nonthyroidal illness (breech delivery, Apgar score unknown, transfer to university medical center for unexplained low heart rate). d Abnormal first 
neonatal screening result (very low T4 SD score); patient was referred to a pediatrician, but not treated; FT4 concentration could not be retrieved. For all measurements, medians and 
means were approximately similar, except for the TSH concentration, which is not distributed normally.
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tients the medical chart mentioned the prescription of 
cortisol treatment for insufficient ACTH reserve. Six of 
these 11 patients were subsequently treated with hydro-
cortisone, 3 after and 3 before initiation of LT4 treatment. 
Two children were prescribed hydrocortisone use during 
stress only. In the 8 patients with an abnormal HP adrenal 
axis test result and available MRI result, 5 were abnormal 
(ectopic posterior pituitary, in combination with pitu-
itary hypoplasia [n = 4] or a thin pituitary stalk in combi-
nation with pituitary hypoplasia [n = 1]). All 3 patients 
with a normal ACTH test result had pituitary hypoplasia.
Discussion
In this large Dutch cohort of children treated with GH 
for apparent isolated GHD, 23 children (6.3%) were pre-
scribed LT4 treatment for presumed CeH within 2 years 
after initiation of GH treatment. Similar to children al-
ready diagnosed with (congenital) MPHD before starting 
GH treatment, approximately three-quarter of these chil-
dren had congenital structural HP abnormalities. In ret-
rospect, 3 of these patients had FT4 concentrations just 
below the reference range interval before the initiation of 
GH treatment, but were prescribed LT4 only after further 
decrease of FT4 concentrations. In children with appar-
ent isolated GHD, not prescribed LT4 treatment after ini-
tiation of GH treatment, a relationship was found be-
tween FT4 concentrations and the presence of anatomic 
pituitary abnormalities. In these children, the lower the 
pre- or post-GH treatment FT4 concentrations were, the 
higher the chance that MRI revealed congenital pituitary 
malformations. In children with the lowest FT4 concen-
trations (one or more times <10 pmol/L), the percentage 
of pituitary abnormalities was even similar to that in chil-
dren with MPHD (75%). If all children with apparent iso-
lated GHD, and a low FT4 (<10 pmol/L), and abnormal 
MRI are considered to have CeH, the percentage of un-
masked CeH around the initiation of GH treatment in-
creases to 7.9% (23 + 6 = 29; 29 of 367 = 7.9%). Several 
children with newly diagnosed CeH were also diagnosed 
with central adrenal insufficiency, and were started on 
hydrocortisone treatment or were prescribed hydrocorti-
sone during periods of stress or illness. Unfortunately, 
neonatal CH screening results were available for only 4 of 
the 23 children prescribed LT4. These 4 children had low-
er neonatal screening T4 concentrations, similar to chil-
dren who were already diagnosed with MPHD before 
starting GH treatment. This supports our hypothesis that 
a (too) low FT4 around the initiation of GH treatment in 
a child with apparent isolated GHD is a very strong pre-
dictor of the presence of MPHD resulting from congeni-
tal, structural pituitary abnormalities. The finding that 
the neonatal CH screening results available in the few 
children with presumed CeH were lower than average 
suggests that the CeH, although probably mild, may have 
been present from birth onwards. However, this observa-
tion needs to be validated in a larger group of patients.
This is not the first study to demonstrate lower thyroid 
hormone concentrations after initiation of GH treatment 
in children with GHD suggestive of CeH [11, 22, 23]. 
However, in all previous studies the children showing this 
phenomenon were already diagnosed with acquired or-
ganic pituitary disease or congenital MPHD. The same 
applies to studies in adults, in which GH treatment was 
found to unmask CeH in patients with known acquired 
organic pituitary disease [4]. Our study is the first to dem-
onstrate this phenomenon in children with presumed iso-
lated GHD; the low FT4 concentrations were the first clue 
for additional functional and/or structural pituitary ab-
normalities. As already mentioned in the introduction, 
Pampanini et al. [15] recently described brain MRI find-
ings in 68 children diagnosed with GHD before the age of 
4 years. All 31 children diagnosed with MPHD had com-
plex pituitary defects, while most of the 37 children diag-
nosed with isolated GHD only showed isolated pituitary 
hypoplasia or even a normal pituitary gland. Children 
with MPHD were diagnosed at a younger age than chil-
dren with isolated GHD. With respect to the presence or 
absence of structural HP abnormalities, the results of our 
study are in line with these results. The children in our 
study diagnosed with MPHD before the initiation of GH 
treatment, and the children diagnosed with CeH after the 
initiation of GH treatment, had a higher percentage of 
“complex defects” than the children diagnosed with prob-
ably isolated GHD.
The Dutch neonatal CH screening consists of a three-
step “T4+TSH+TBG” approach, enabling calculation of 
the so-called “T4/TBG ratio” [16]. The 29 children in this 
study with (probable) CeH and not detected by neonatal 
screening had a T4 concentration, or a T4/TBG ratio 
above the screening cutoffs. If these 29 children really had 
(mild) congenital CeH, this would raise the Dutch preva-
lence from 1 case per 16,404 to approximately 1 case per 
13,211 [16]. Increasing neonatal screening cutoffs would 
probably enable the detection of these mild cases of CeH 
but would result in an increase in false-positive test re-
sults.
Genetic results were available in 2 of the 23 children 
treated with LT4 after initiation of GH treatment. One 
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child had a mutation in IGSF1, another in POU1F1, both 
well-known genetic causes of congenital CeH [24–27]. 
Like the abnormal pituitary morphology in the other chil-
dren, these genetic findings support the true nature of the 
CeH in these 2 children.
Major strengths of our study are the large sample size 
(n = 456), the high percentage of participating children 
and parents (74.8%), and the fact that we were able to re-
cruit participants from a complete, national cohort of 
children with GH treatment for apparent isolated GHD 
over a period of 10 years. However, our study has some 
limitations. Firstly, diagnosing CeH is not easy. Although 
a (very) low FT4 in combination with a normal TSH con-
centration in the absence of nonthyroidal illness is strong-
ly suggestive of this condition, FT4 concentrations around 
the lower limit of the reference interval are often difficult 
to interpret [27, 28]. In addition, the decision to start LT4 
treatment in the GH-treated children were made by dif-
ferent pediatric endocrinologists and pediatricians, using 
different FT4 assays and reference intervals. This may 
have resulted in over- as well as underestimation of the 
number of CeH cases. Furthermore, the dataset unfortu-
nately was not complete. Not all children with isolated 
GHD underwent MRI of the pituitary region. This may 
have led to over- or underestimation of the number of 
children with abnormal pituitary morphology. Lastly, 
neonatal CH screening results were retrieved in only 50% 
of the included children, and one third had to be exclud-
ed from further analyses. This clearly affects the validity 
of the conclusions.
In summary, in this large retrospective cohort study, 
CeH was diagnosed in at least 6.3% of children with GH 
treatment for apparent isolated GHD. Approximately 
75% of these children had congenital structural pituitary 
abnormalities. The same percentage of pituitary abnor-
malities was found in children with a low or low normal 
FT4 concentration, not yet diagnosed with CeH. These 
findings suggest that low FT4 concentrations around the 
initiation of GH treatment in children with congenital 
GHD are a predictor of the presence of congenital struc-
tural pituitary abnormalities and, with that, the diagnosis 
MPHD. FT4 concentrations around the lower limit of the 
reference interval before GH treatment may indicate CeH 
and require close follow-up and, if necessary, additional 
diagnostic testing. Although we concur that brain imag-
ing should be performed in every child with apparent iso-
lated GHD, this may be postponed until a later age if FT4 
concentrations are repeatedly above the lower tertile of 
the reference interval, and if periodic adrenal axis testing 
is normal. Obvious exceptions are children suspected of 
having a space-occupying brain lesion. Although our re-
sults suggest that children diagnosed with CeH around 
the initiation of GH treatment already had (mild) CeH in 
the neonatal period, this needs further investigation.
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